In the News

Russo Partners works at the intersection of science, medicine, and media. The stories below reflect the conversations we help shape covering breakthroughs in biopharma, digital health, healthcare, and beyond.


BioTech Nation

 | 

September 8, 2026

A Different Approach to Treating Gout…Dr. James Mackay, Co-Founder, CEO, & President, Crystalys Therapeutics

On this episode of BioTech Nation…Dr. James Mackay joins to talk about the progress Crystalys Therapeutics is making in the…

For more 

GEN News

 | 

August 27, 2026

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

Aprea Therapeutics is accelerating enrollment in its ongoing Phase I trial of its targeted cancer therapy APR-1051, one of the…

For more 

GEN News

 | 

August 12, 2026

Next 10 U.S. Biopharma Clusters

For the first time, GEN examines the top regions and top states just below the 10 largest regions for life…

For more 

Clarivate

 | 

August 5, 2026

7 weight loss companies to watch: innovators in GLP-1s and beyond

The market for weight loss treatments is a crowded one, and new entrants are piling in. The latest in our…

For more 

Pulse 2.0

 | 

August 5, 2026

Ratio Therapeutics Raises $70 Million Series C To Advance Radiopharmaceutical Pipeline

Ratio Therapeutics has raised $70 million in Series C funding to advance its targeted radiopharmaceutical pipeline and expand its manufacturing…

For more 

San Diego Union Tribune

 | 

July 28, 2026

His father suffered from gout in silence. Now a San Diego scientist is bringing the cure home

As a child, James Mackay watched his father struggle just to stand up. “You shouldn’t have eaten this or that,”…

For more 

The Wall Street Journal

The Wall Street Journal

 | 

July 23, 2026

Biotech Startup Gets $130 Million to Settle ‘Unfinished Business’

James Mackay’s previous effort to provide gout patients with a novel treatment ended in disappointment. Venture capitalists are helping him…

For more 

Biopharma Dive

 | 

July 22, 2026

Crystalys nets $130M more to push gout drug through late-stage tests

Less than a year after landing a big funding round, Crystalys Therapeutics has banked a second one, announcing Wednesday a…

For more 

Scrip Citeline

 | 

July 16, 2026

BIO 2026: Catching Up With Vaxart, Aphaia, Connect Biopharma, Kyverna And Chugai

The recent BIO International Convention offered an opportunity to check in with biopharmaceutical companies about near-term milestones and long-term strategies. Scrip spoke…

For more 

The Wall Street Journal

The Wall Street Journal

 | 

July 16, 2026

Biotech Venture Funding Roars Back

Biotechnology venture funding is surging, driven by an explosion of mergers and acquisitions and a revival of initial public offerings in…

For more 

Next

Upcoming Events

Our team is active across the industry year-round. Find us at these upcoming conferences and events.


BioFuture

October 27-28, 2026

New York, NY